Clinical history of cancer-associated splanchnic vein thrombosis.
anticoagulants
mesenteric veins
neoplasms
portal vein
splanchnic circulation
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
03
12
2020
received:
25
08
2020
accepted:
07
12
2020
pubmed:
12
12
2020
medline:
15
5
2021
entrez:
11
12
2020
Statut:
ppublish
Résumé
Cancer represents a risk factor for splanchnic vein thrombosis (SVT) and usual site venous thromboembolism (VTE). To compare characteristics and outcomes of patients with cancer-associated SVT and usual site VTE. Patients with solid cancer and SVT were enrolled in an international, prospective registry between May 2008 and January 2012. The comparison cohort included (1:1 ratio) patients with solid cancer and usual site VTE treated at two thrombosis centers who had a minimum of 12 months follow-up at December 2019 or experienced one of the outcomes within 12 months follow-up. Recurrent VTE, major bleeding, and all-cause mortality were evaluated at 12-month follow-up. A total of 264 patients (132 in each cohort) were enrolled. Patients with SVT were less likely to have metastatic disease (36.1% vs 72.5%) or receive cancer therapy at thrombosis diagnosis (29.6% vs 64.9%). The most frequent cancer types were hepatobiliary and pancreatic in the SVT cohort and gastrointestinal in the usual site VTE cohort. Fewer patients with SVT received anticoagulation (68.9% vs 99.2%), and treatment duration was shorter (6.0 vs 11.0 months). The cumulative incidence of major bleeding (2.3% vs 4.7%) was nonsignificantly lower in the SVT cohort, whereas recurrent thrombosis (4.7% vs 5.5%) and all-cause mortality (41.7% vs 39.4%) were comparable between the two cohorts. The risk of recurrent thrombosis and bleeding appears to be similar in cancer patients with SVT and cancer patients with usual site VTE, despite some differences in baseline characteristics and anticoagulant treatment. Further prospective studies are warranted to confirm these findings.
Sections du résumé
BACKGROUND
Cancer represents a risk factor for splanchnic vein thrombosis (SVT) and usual site venous thromboembolism (VTE).
OBJECTIVES
To compare characteristics and outcomes of patients with cancer-associated SVT and usual site VTE.
PATIENTS/METHODS
Patients with solid cancer and SVT were enrolled in an international, prospective registry between May 2008 and January 2012. The comparison cohort included (1:1 ratio) patients with solid cancer and usual site VTE treated at two thrombosis centers who had a minimum of 12 months follow-up at December 2019 or experienced one of the outcomes within 12 months follow-up. Recurrent VTE, major bleeding, and all-cause mortality were evaluated at 12-month follow-up.
RESULTS
A total of 264 patients (132 in each cohort) were enrolled. Patients with SVT were less likely to have metastatic disease (36.1% vs 72.5%) or receive cancer therapy at thrombosis diagnosis (29.6% vs 64.9%). The most frequent cancer types were hepatobiliary and pancreatic in the SVT cohort and gastrointestinal in the usual site VTE cohort. Fewer patients with SVT received anticoagulation (68.9% vs 99.2%), and treatment duration was shorter (6.0 vs 11.0 months). The cumulative incidence of major bleeding (2.3% vs 4.7%) was nonsignificantly lower in the SVT cohort, whereas recurrent thrombosis (4.7% vs 5.5%) and all-cause mortality (41.7% vs 39.4%) were comparable between the two cohorts.
CONCLUSIONS
The risk of recurrent thrombosis and bleeding appears to be similar in cancer patients with SVT and cancer patients with usual site VTE, despite some differences in baseline characteristics and anticoagulant treatment. Further prospective studies are warranted to confirm these findings.
Identifiants
pubmed: 33306241
doi: 10.1111/jth.15214
pii: S1538-7836(22)00709-7
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
983-991Informations de copyright
© 2020 International Society on Thrombosis and Haemostasis.
Références
Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Medicine. 2012;9:E1001275.
Di Nisio M, Ferrante N, De Tursi M, et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost. 2010;104:1049-1054.
Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost. 2011;106:371-378.
Afzal A, Suhong L, Gage BF, et al. Splanchnic vein thrombosis predicts worse survival in patients with advanced pancreatic cancer. Thromb Res. 2020;185:125-131.
Singh R, Sousou T, Mohile S, Khorana AA. High rates of symptomatic and incidental thromboembolic events in gastrointestinal cancer patients. J Thromb Haemost. 2010;8:1879-1881.
Godinho J, Casa-Nova M, Moreira-Pinto J, et al. ONKOTEV score as a predictive tool for thromboembolic events in pancreatic cancer-a retrospective analysis. Oncologist. 2020;25:E284-E290.
Douma RA, Kok MG, Verberne LM, Kamphuisen PW, Buller HR. Incidental venous thromboembolism in cancer patients: prevalence and consequence. Thromb Res. 2010;125:E306-E309.
Khorana AA. Cancer-associated thrombosis: updates and controversies. Hematology Am Soc Hematol Educ Program. 2012;2012:626-630.
Valeriani E, Riva N, Di Nisio M, Ageno W. Splanchnic vein thrombosis: current perspectives. Vasc Health Risk Manag. 2019;15:449-461.
Ageno W, Squizzato A, Togna A, et al. Incidental diagnosis of a deep vein thrombosis in consecutive patients undergoing a computed tomography scan of the abdomen: a retrospective cohort study. J Thromb Haemost. 2012;10:158-160.
Sogaard KK, Farkas DK, Pedersen L, Sorensen HT. Splanchnic venous thrombosis is a marker of cancer and a prognostic factor for cancer survival. Blood. 2015;126:957-963.
Ageno W, Riva N, Schulman S, et al. Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry. JAMA Intern Med. 2015;175:1474-1480.
Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific Standardization Committee of the International Society on Thrombosis Haemostasis. Definition of Major Bleeding in Clinical Investigations of Antihemostatic Medicinal Products in Non-Surgical Patients. J Thromb Haemost. 2005;3:692-694.
Ay C, Posch F, Kaider A, Zielinski C, Pabinger I. Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality. J Thromb Haemost. 2015;13:390-397.
Coviello E.STCOMPET: Stata Module to Generate Cumulative Incidence in Presence of Competing Events. Statistical Software Components S431301, Boston College Department of Economics; 2003.
Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. Stata J. 2004;4:103-112.
Clayton P.STCOMLIST: Stata Module to List Cumulative Function in Presence of Competing Risks. Statistical Software Components S458292, Boston College Department of Economics; 2017.
Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
Gray RJ.Cmprsk: Subdistribution Analysis of Competing Risks. R Package Version 2.2-9; 2019.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
Moons KG, Kengne AP, Woodward M, et al. Risk prediction models: i. development, internal validation, and assessing the incremental value of a new (bio)marker. Heart. 2012;98:683-690.
R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. 2020.
Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382:1599-1607.
Giustozzi M, Agnelli G, Del Toro-Cervera J, et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost. 2020;120:1128-1136.
Raskob GE, Van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615-624.
Heit JA, Lahr BD, Ashrani AA, Petterson TM, Bailey KR. Predictors of venous thromboembolism recurrence, adjusted for treatments and interim exposures: a population-based case-cohort study. Thromb Res. 2015;136:298-307.
Lee AYY. When can we stop anticoagulation in patients with cancer-associated thrombosis? Blood. 2017;130:2484-2490.
Francis CW, Kessler CM, Goldhaber SZ, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN study. J Thromb Haemost. 2015;13:1028-1035.
Chee CE, Ashrani AA, Marks RS, et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood. 2014;123:3972-3978.
Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-3488.
Di Nisio M, Van Es N, Carrier M, et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE cancer study. J Thromb Haemost. 2019;17:1866-1874.
Di Nisio M, Valeriani E, Riva N, Schulman S, Beyer-Westendorf J, Ageno W. Anticoagulant therapy for splanchnic vein thrombosis. J Thromb Haemost. 2020;18:1562-1568.
Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38:496-520.
Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36:2017-2023.
Kamphuisen PW, Beyer-Westendorf J. Bleeding complications during anticoagulant treatment in patients with cancer. Thromb Res. 2014;133(Suppl 2):S49-S55.
Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology. 2017;153: 480-7 E1.
Qi X, De Stefano V, Li H, Dai J, Guo X, Fan D. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015;26:23-29.
Senzolo M, Riva N, Dentali F, et al. Long-term outcome of splanchnic vein thrombosis in cirrhosis. Clin Transl Gastroenterol. 2018;9:176.
Valeriani E, Di Nisio M, Riva N, et al. Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis. Blood. 2020. Online ahead of print.
Sogaard KK, Darvalics B, Horvath-Puho E, Sorensen HT. Survival after splanchnic vein thrombosis: a 20-year nationwide cohort study. Thromb Res. 2016;141:1-7.
Lee AY, Levine MN, Baker RI, et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer. low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153. https://doi.org/10.1056/Nejmoa025313